Biomed Central Ltd

SHERPA: Unknown

People

  1. Vickers
    Vickers
  2. Postow
    Postow
  3. D'Angelo
    D'Angelo
  4. Offit
    Offit
  5. Budhu
    Budhu
  6. Motzer
    Motzer
  7. Shoushtari
    Shoushtari
  8. Cheung
    Cheung
  9. Voss
    Voss
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (560)
  2. Solid Tumor Oncology Division (456)
  3. GSK Faculty (293)
  4. Sloan Kettering Institute Postdocs (193)
  5. Population Sciences Research Program (157)
  6. Hematologic Malignancies, Division of (155)
  7. Epidemiology and Biostatistics (152)
  8. Melanoma and Immunotherapeutics Service (148)
  9. Survivorship Research (120)
  10. Surgery (119)
Search Within
Formats
  1. Journal Article (745)
  2. Meeting Abstract (257)
  3. Review (40)
  4. Guidelines (20)
  5. Editorial (10)
  6. Research Letter (7)
  7. Correspondence (4)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (560)
  2. Solid Tumor Oncology Division (456)
  3. GSK Faculty (293)
  4. Sloan Kettering Institute Postdocs (193)
  5. Population Sciences Research Program (157)
  6. Hematologic Malignancies, Division of (155)

More Groups

People
  1. Jedd Wolchok (83)
  2. Taha Merghoub (55)
  3. Andrew Vickers (44)
  4. Michael Postow (43)
  5. Matthew Hellmann (30)
  6. Sandra D'Angelo (25)

More People

Years
  1. 2025 (33)
  2. 2024 (60)
  3. 2023 (44)
  4. 2022 (122)
  5. 2021 (91)
  6. 2020 (99)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (407)
  2. Breast Cancer Research (67)
  3. BMC Cancer (64)
  4. Genome Biology (47)
  5. Journal of Hematology & Oncology (43)
  6. Journal of Translational Medicine (35)

More Publications

Results (1085)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Apr-246 induces an increase in tumor immunogenicity in a p53 independent manner
    Meeting Abstract

    Venkatesh, D.; Michels, J.; Lu, C.; Budhu, S.; George, M.; Ouerfelli, O.; Abrahmsen, L.; Zappasodi, R.; Wolchok, J.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • LDH inhibition improves response to CTLA-4 blockade by enhancing effector T cell activity and impairing regulatory T cell suppression
    Meeting Abstract

    Verma, S.; Serganova, I.; Budhu, S.; Dong, L.; Mangarin, L.; Ko, M.; Blasberg, R.; Zappasodi, R.; Wolchok, J.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Targeting LSD1 rescues MHC-I antigen presentation and overcomes resistance to PD-L1 blockade therapy in small cell lung cancer
    Meeting Abstract

    Nguyen, E.; Chow, A.; Rudin, C.; Sen, T.; Taniguchi, H.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Pharmacokinetic and pharmacodynamic data from a phase 1 study of CI-8993 anti-vista antibody in patients with advanced solid tumors
    Meeting Abstract

    Noelle, R.; Johnson, M.; Rodon, J.; Zauderer, M.; Lewis, L.; Severgnini, M.; Parker, J.; Lane, M.; von Roemeling, R.; Martin, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • ITIL-306-201: A multicenter, first-in-human phase 1a/1b study of ITIL-306, an engineered autologous tumor-infiltrating lymphocyte (TIL) cell therapy product, in adults with advanced solid tumor
    Meeting Abstract

    Ward, J.; Ghobadi, A.; Liao, J.; Schoenfeld, A.; Tykodi, S.; Jiang, Y.; Le Gall, J.; Alvarez-Rodriguez, R.; Sherman, M.; Singson, T.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Botensilimab, a novel innate/adaptive immune activator, plus or minus balstilimab (anti-PD-1) in "cold" and I-O refractory metastatic solid tumors
    Meeting Abstract

    Wilky, B.; El-Khoueiry, A.; Bullock, A.; Tsimberidou, A.; Mahadevan, D.; Margolin, K.; Trent, J.; Bockorny, B.; Moser, J.; Hosein, P.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti-PD-1) in patients with advanced solid tumors: Initial dose-escalation results
    Meeting Abstract

    Johnson, M.; Lakhani, N.; Girda, E.; Olszanski, A.; Fong, L.; Han, H.; Casey, K.; Li, S.; Visich, J.; Skokos, D.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • A multicohort phase 1b study (STELLAR-002) of XL092 in combination with immunotherapy in patients with advanced solid tumors
    Meeting Abstract

    McGregor, B.; Choueiri, T.; Shah, N.; Bajaj, A.; Chahoud, J.; O'Neil, B.; Michalski, J.; Garmezy, B.; Jin, L.; Aziz, U.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • MEDI1191 (IL-12 MRNA) induces peripheral and intratumoral immunostimulatory effect in patients with cutaneous or subcutaneous (c/sc) lesions
    Meeting Abstract

    Abadier, M.; Jennings, E.; Eyles, J.; Martin, P.; Pilataxi, F.; Wu, Y.; Chen, X.; Azaro, A.; Ridgway, B.; Phillips, M.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Exploratory platform trial to evaluate immunotherapy combinations with chemotherapy for the treatment of patients with previously untreated metastatic pancreatic adenocarcinoma (REVOLUTION)
    Meeting Abstract

    Lyman, J.; O'Reilly, E.; Wainberg, Z.; Fisher, G.; Wolff, R.; Ko, A.; O'Hara, M.; Singh, H.; Amaravadi, R.; Kimmelman, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save